59 related articles for article (PubMed ID: 27376492)
1. New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2.
Pires ADRA; Lecerf-Schmidt F; Guragossian N; Pazinato J; Gozzi GJ; Winter E; Valdameri G; Veale A; Boumendjel A; Di Pietro A; Pérès B
Eur J Med Chem; 2016 Oct; 122():291-301. PubMed ID: 27376492
[TBL] [Abstract][Full Text] [Related]
2. Chromones bearing amino acid residues: Easily accessible and potent inhibitors of the breast cancer resistance protein ABCG2.
Roussel E; Moréno A; Altounian N; Philouze C; Pérès B; Thomas A; Renaudet O; Falson P; Boumendjel A
Eur J Med Chem; 2020 Sep; 202():112503. PubMed ID: 32653696
[TBL] [Abstract][Full Text] [Related]
3. Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.
Valdameri G; Genoux-Bastide E; Peres B; Gauthier C; Guitton J; Terreux R; Winnischofer SM; Rocha ME; Boumendjel A; Di Pietro A
J Med Chem; 2012 Jan; 55(2):966-70. PubMed ID: 22165858
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2.
Winter E; Lecerf-Schmidt F; Gozzi G; Peres B; Lightbody M; Gauthier C; Ozvegy-Laczka C; Szakacs G; Sarkadi B; Creczynski-Pasa TB; Boumendjel A; Di Pietro A
J Med Chem; 2013 Dec; 56(24):9849-60. PubMed ID: 24304387
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
Krapf MK; Gallus J; Wiese M
Eur J Med Chem; 2017 Oct; 139():587-611. PubMed ID: 28841513
[TBL] [Abstract][Full Text] [Related]
6. MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts.
Payen L; Honorat M; Guitton J; Gauthier C; Bouard C; Lecerf-Schmidt F; Peres B; Terreux R; Gervot H; Rioufol C; Boumendjel A; Puisieux A; Di Pietro A
Oncotarget; 2014 Dec; 5(23):11957-70. PubMed ID: 25474134
[TBL] [Abstract][Full Text] [Related]
7. Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.
Winter E; Devantier Neuenfeldt P; Chiaradia-Delatorre LD; Gauthier C; Yunes RA; Nunes RJ; Creczynski-Pasa TB; Di Pietro A
J Med Chem; 2014 Apr; 57(7):2930-41. PubMed ID: 24611893
[TBL] [Abstract][Full Text] [Related]
8. Optimization of the chromone scaffold through QSAR and docking studies: Identification of potent inhibitors of ABCG2.
Roussel E; Tran-Nguyen VK; Bouhedjar K; Dems MA; Belaidi A; Matougui B; Peres B; Azioune A; Renaudet O; Falson P; Boumendjel A
Eur J Med Chem; 2019 Dec; 184():111772. PubMed ID: 31630055
[TBL] [Abstract][Full Text] [Related]
9. Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2.
Boumendjel A; Macalou S; Ahmed-Belkacem A; Blanc M; Di Pietro A
Bioorg Med Chem; 2007 Apr; 15(8):2892-7. PubMed ID: 17317193
[TBL] [Abstract][Full Text] [Related]
10. The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
Kraege S; Stefan K; Juvale K; Ross T; Willmes T; Wiese M
Eur J Med Chem; 2016 Jul; 117():212-29. PubMed ID: 27100033
[TBL] [Abstract][Full Text] [Related]
11. Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors.
Köhler SC; Vahdati S; Scholz MS; Wiese M
Eur J Med Chem; 2018 Feb; 146():483-500. PubMed ID: 29407974
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).
Krapf MK; Wiese M
J Med Chem; 2016 Jun; 59(11):5449-61. PubMed ID: 27148793
[TBL] [Abstract][Full Text] [Related]
13. ABCG2: recent discovery of potent and highly selective inhibitors.
Lecerf-Schmidt F; Peres B; Valdameri G; Gauthier C; Winter E; Payen L; Di Pietro A; Boumendjel A
Future Med Chem; 2013 Jun; 5(9):1037-45. PubMed ID: 23734686
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interactions in mice between irinotecan and MBL-II-141, an ABCG2 inhibitor.
Hénin E; Honorat M; Guitton J; Di Pietro A; Payen L; Tod M
Biopharm Drug Dispos; 2017 Jul; 38(5):351-362. PubMed ID: 28207160
[TBL] [Abstract][Full Text] [Related]
15. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
D'Cunha R; Bae S; Murry DJ; An G
Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
[TBL] [Abstract][Full Text] [Related]
16. 6-halogenochromones bearing tryptamine: one-step access to potent and highly selective inhibitors of breast cancer resistance protein.
Valdameri G; Genoux-Bastide E; Gauthier C; Peres B; Terreux R; Winnischofer SM; Rocha ME; Di Pietro A; Boumendjel A
ChemMedChem; 2012 Jul; 7(7):1177-80. PubMed ID: 22615192
[No Abstract] [Full Text] [Related]
17. A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo.
Anreddy N; Patel A; Zhang YK; Wang YJ; Shukla S; Kathawala RJ; Kumar P; Gupta P; Ambudkar SV; Wurpel JN; Chen ZS; Guo H
Oncotarget; 2015 Nov; 6(36):39276-91. PubMed ID: 26515463
[TBL] [Abstract][Full Text] [Related]
18. Optimization of Acryloylphenylcarboxamides as Inhibitors of ABCG2 and Comparison with Acryloylphenylcarboxylates.
Kraege S; Stefan K; Köhler SC; Wiese M
ChemMedChem; 2016 Nov; 11(22):2547-2558. PubMed ID: 27785905
[TBL] [Abstract][Full Text] [Related]
19. Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.
Wu CP; Hsieh YJ; Hsiao SH; Su CY; Li YQ; Huang YH; Huang CW; Hsieh CH; Yu JS; Wu YS
Mol Pharm; 2016 Mar; 13(3):784-94. PubMed ID: 26796063
[TBL] [Abstract][Full Text] [Related]
20. The More the Better-Investigation of Polymethoxylated
Stockmann P; Kuhnert L; Leinung W; Lakoma C; Scholz B; Paskas S; Mijatović S; Maksimović-Ivanić D; Honscha W; Hey-Hawkins E
Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
